Evicenter
Enhertu (fam-trastuzumab deruxtecan-nxki), All indications
Manufacturer
Daiichi Sankyo, Inc.; AstraZeneca Pharmaceuticals LP
Prescribing information
Enhertu (opens in a new tab)
Questions
31
Last updated

All questions

Dosing and administration: Enhertu (fam-trastuzumab deruxtecan-nxki), all indications

7 questions · 4 sources

Premedication

Does Enhertu need anti-nausea premedication?

Dosing

What are the Enhertu dose reduction levels?

Note: The first column (5.4 mg/kg starting dose) applies to breast cancer, including HER2-low and HER2-ultralow metastatic breast cancer; the second column applies to gastric cancer.

What if an Enhertu dose is missed or delayed?

Administration

How long does an Enhertu infusion take?

Before treatment

What should be checked before starting Enhertu and during treatment?

Preparation

How is Enhertu reconstituted and diluted?

Can Enhertu be substituted for trastuzumab or ado-trastuzumab emtansine?